Obesity News

In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported.

ORLANDO, Fla. — For individuals hospitalized with intracerebral hemorrhage, increased caloric intake that led to an increase in weight was associated with higher odds of survival after 3 months, according to a poster.

In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial.

Intermittent and continuous energy restriction diets both improved cardiometabolic measures and reduced symptoms of depression and disordered eating among adolescents with obesity, according to findings published in JAMA Pediatrics.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

Obesity prevalence among adults remained high in the United States in 2023, with one in three adults living with obesity in 23 states, according to new CDC data.

Exposure to high amounts of certain per- and polyfluoroalkyl substances during pregnancy may cause long-term increases in weight and fat mass, according to research published in The Journal of Clinical Endocrinology & Metabolism.

Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the Study of Diabetes annual meeting.

Young children at high genetic risk for type 1 diabetes may be more likely to progress to the disease based on their dietary intake, according to a presenter at the European Association for the Study of Diabetes annual meeting.